Telemedicine for type 2 diabetes during COVID-19 pandemic: experience from a tertiary diabetes center.
Minerva Endocrinol (Torino)
; 2024 Jan 29.
Article
en En
| MEDLINE
| ID: mdl-38287789
ABSTRACT
BACKGROUND:
Telemedicine was largely employed during COVID-19 pandemic to guarantee continuity of care in a period of dramatic reduction of face-to-face visits. The aim of this study was to describe the clinical characteristics of a cohort of patients with type 2 diabetes followed by tele-visits and to evaluate the changes in the glyco-metabolic control during a 12-month follow-up.METHODS:
This retrospective observational study included 136 adults aged >18 years with at least three tele-visits over a 12-month follow-up period, in a Diabetes Center of the Southern Italy, from April 2020 to March 2022. Data related to glycemic and lipid profile, therapy, presence of micro or macrovascular complications, and other clinical features were extracted at three time points, at first visit (T0), after 6 months (T1) and after 12 months (T2).RESULTS:
Mean diabetes duration and median HbA1c values were 11.6 years and 7.0%, respectively. Thirty-eight participants (27.9%) presented macro- or microvascular complications. Glycemic control remained stable over time, without clinically significant changes of HbACONCLUSIONS:
People with type 2 diabetes followed by telemedicine were adults with fair glucose control generally free from chronic complications, whose diabetes control did not worsen during a 12-month follow-up.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Observational_studies
Idioma:
En
Revista:
Minerva Endocrinol (Torino)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Italia